KRYSTAL-1

NCT03785249 📎

Regimen

Experimental
Adagrasib 600 mg BID + cetuximab (combination cohort); adagrasib monotherapy
Control
single-arm (non-randomized; two cohorts compared)

Population

KRAS G12C-mutant metastatic CRC, 3L+ (≥2 prior lines); specific KRAS G12C testing required.

Key finding

Monotherapy (n=44): ORR 19% (95% CI 8–33), median duration of response 4.3 months (2.3–8.3), median PFS 5.6 months (4.1–8.3); combination adagrasib+cetuximab (n=32): ORR 46% (95% CI 28–66), median duration of response 7.6 months (5.7–NE), median PFS 6.9 months (5.4–8.1); grade 3–4 TRAEs: 34% (mono) vs 16% (combo); no grade 5 AEs.

Source: PMID 36546659

Timeline

    Guideline citations

    • NCCN Colon (p.20)
    • NCCN Rectal (p.26)